In National Advertising Division Challenge, Striker Pharmacy Voluntarily Discontinues Claims for Compounded Tirzepatide
New York, NY, June 3, 2025 - BBB National Programs’ National Advertising Division reviewed a challenge brought by Eli Lilly and Company regarding express and implied advertising claims made by Striker Pharmacy, LLC concerning the benefits, efficacy, and safety of its compounded tirzepatide medication.
The challenged health-related claims, regarding the benefits, efficacy, and safety of Striker Pharmacy’s compounded tirzepatide medication, appeared on Striker Pharmacy’s website and Instagram pages.
During the inquiry, Striker Pharmacy informed the National Advertising Division (NAD) that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.
The challenged health-related claims, regarding the benefits, efficacy, and safety of Striker Pharmacy’s compounded tirzepatide medication, appeared on Striker Pharmacy’s website and Instagram pages.
During the inquiry, Striker Pharmacy informed the National Advertising Division (NAD) that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.